SOST and aggressive systemic mastocytosis: Additionally, we observed significantly higher sclerostin concentrations in the plasma of patients with a diagnosis of ASM (both de novo and in progression), SM-AHN, and SSM compared to patients with less advanced mastocytosis: ISM and CM (34.2 vs. 19.3 [pmol/l]).